Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neutrophils | 5 | 2019 | 835 | 1.770 |
Why?
|
| Intestinal Mucosa | 5 | 2016 | 1081 | 1.380 |
Why?
|
| Extracellular Traps | 2 | 2019 | 25 | 1.200 |
Why?
|
| Dysbiosis | 3 | 2016 | 134 | 1.100 |
Why?
|
| Escherichia coli Infections | 3 | 2016 | 241 | 0.910 |
Why?
|
| Bone Marrow Cells | 2 | 2019 | 943 | 0.820 |
Why?
|
| Annexin A1 | 2 | 2012 | 39 | 0.730 |
Why?
|
| Citrobacter rodentium | 4 | 2015 | 10 | 0.710 |
Why?
|
| Colitis | 5 | 2015 | 340 | 0.680 |
Why?
|
| Escherichia coli | 2 | 2016 | 1203 | 0.670 |
Why?
|
| Colitis, Ulcerative | 2 | 2012 | 268 | 0.640 |
Why?
|
| Calcitriol | 2 | 2015 | 127 | 0.610 |
Why?
|
| Vitamin D Deficiency | 2 | 2015 | 115 | 0.580 |
Why?
|
| Enterobacteriaceae Infections | 3 | 2015 | 69 | 0.570 |
Why?
|
| Microbial Interactions | 1 | 2015 | 17 | 0.530 |
Why?
|
| Lactobacillus | 1 | 2015 | 58 | 0.530 |
Why?
|
| Gastrointestinal Tract | 3 | 2015 | 324 | 0.460 |
Why?
|
| Gain of Function Mutation | 3 | 2023 | 126 | 0.440 |
Why?
|
| Lipoxins | 1 | 2012 | 20 | 0.430 |
Why?
|
| Probiotics | 2 | 2014 | 228 | 0.410 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2014 | 675 | 0.410 |
Why?
|
| Crohn Disease | 1 | 2015 | 351 | 0.390 |
Why?
|
| Prostaglandin D2 | 1 | 2010 | 26 | 0.380 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 554 | 0.380 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 598 | 0.360 |
Why?
|
| Autoimmune Diseases | 2 | 2023 | 402 | 0.350 |
Why?
|
| NF-kappa B | 4 | 2023 | 1549 | 0.340 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2011 | 521 | 0.330 |
Why?
|
| Homeostasis | 2 | 2012 | 950 | 0.310 |
Why?
|
| Myeloblastin | 1 | 2007 | 64 | 0.300 |
Why?
|
| Mice, Inbred C57BL | 8 | 2016 | 6942 | 0.290 |
Why?
|
| Disease Models, Animal | 5 | 2015 | 7222 | 0.290 |
Why?
|
| Transcription Factor RelB | 2 | 2023 | 16 | 0.280 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2019 | 238 | 0.280 |
Why?
|
| Cyclooxygenase 2 | 4 | 2012 | 483 | 0.270 |
Why?
|
| Bacterial Adhesion | 2 | 2016 | 147 | 0.250 |
Why?
|
| STAT1 Transcription Factor | 2 | 2022 | 156 | 0.240 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 703 | 0.240 |
Why?
|
| Inflammation | 4 | 2015 | 2522 | 0.240 |
Why?
|
| Actinobacteria | 2 | 2015 | 13 | 0.240 |
Why?
|
| Retinal Dystrophies | 1 | 2023 | 8 | 0.230 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 2992 | 0.220 |
Why?
|
| Osteochondrodysplasias | 1 | 2023 | 77 | 0.220 |
Why?
|
| Host-Pathogen Interactions | 2 | 2015 | 314 | 0.220 |
Why?
|
| Interferon Type I | 1 | 2023 | 250 | 0.210 |
Why?
|
| Mice | 10 | 2023 | 34495 | 0.210 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2022 | 73 | 0.190 |
Why?
|
| Animals | 14 | 2023 | 59536 | 0.190 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2020 | 54 | 0.190 |
Why?
|
| Folic Acid | 1 | 2023 | 349 | 0.190 |
Why?
|
| HL-60 Cells | 2 | 2014 | 302 | 0.190 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2020 | 107 | 0.180 |
Why?
|
| Autoantibodies | 1 | 2023 | 576 | 0.180 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2019 | 62 | 0.180 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2019 | 102 | 0.170 |
Why?
|
| Hydrogen Sulfide | 2 | 2009 | 10 | 0.170 |
Why?
|
| Pancreatic Elastase | 1 | 2019 | 34 | 0.170 |
Why?
|
| Colon | 3 | 2012 | 670 | 0.170 |
Why?
|
| Inflammation Mediators | 2 | 2012 | 423 | 0.170 |
Why?
|
| Microbiota | 2 | 2015 | 547 | 0.170 |
Why?
|
| Dextran Sulfate | 2 | 2015 | 72 | 0.160 |
Why?
|
| Caco-2 Cells | 2 | 2015 | 158 | 0.160 |
Why?
|
| Guanylate Cyclase | 1 | 2017 | 74 | 0.150 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2017 | 113 | 0.140 |
Why?
|
| Up-Regulation | 3 | 2012 | 2450 | 0.140 |
Why?
|
| Gammaproteobacteria | 1 | 2015 | 19 | 0.130 |
Why?
|
| Drug Design | 2 | 2008 | 375 | 0.130 |
Why?
|
| Electric Conductivity | 1 | 2015 | 94 | 0.130 |
Why?
|
| Cell Membrane Permeability | 1 | 2015 | 122 | 0.130 |
Why?
|
| Bacteriological Techniques | 1 | 2015 | 121 | 0.120 |
Why?
|
| Mouth Mucosa | 1 | 2015 | 216 | 0.120 |
Why?
|
| Mouth | 1 | 2015 | 122 | 0.120 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2014 | 226 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 1217 | 0.120 |
Why?
|
| DNA | 1 | 2021 | 2693 | 0.110 |
Why?
|
| Cyclooxygenase 1 | 2 | 2010 | 67 | 0.110 |
Why?
|
| Cell Line | 2 | 2014 | 5114 | 0.110 |
Why?
|
| Intestinal Diseases | 1 | 2014 | 121 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 1146 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2023 | 5539 | 0.110 |
Why?
|
| Phagocytosis | 1 | 2014 | 260 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 3639 | 0.110 |
Why?
|
| Receptors, Lipoxin | 1 | 2012 | 5 | 0.110 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2012 | 11 | 0.110 |
Why?
|
| RNA, Messenger | 2 | 2015 | 6150 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1165 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 1062 | 0.110 |
Why?
|
| Biodiversity | 1 | 2012 | 91 | 0.100 |
Why?
|
| Granulocytes | 1 | 2012 | 224 | 0.100 |
Why?
|
| Histones | 1 | 2019 | 1466 | 0.100 |
Why?
|
| Humans | 19 | 2023 | 261506 | 0.100 |
Why?
|
| Mucin-2 | 1 | 2011 | 62 | 0.100 |
Why?
|
| Metagenome | 1 | 2012 | 176 | 0.100 |
Why?
|
| Interferon-gamma | 2 | 2017 | 1144 | 0.100 |
Why?
|
| Bifidobacterium | 1 | 2011 | 64 | 0.100 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 360 | 0.100 |
Why?
|
| Peptic Ulcer | 1 | 2011 | 140 | 0.090 |
Why?
|
| Receptors, Prostaglandin | 1 | 2010 | 29 | 0.090 |
Why?
|
| Lipocalins | 1 | 2010 | 54 | 0.090 |
Why?
|
| Jejunum | 1 | 2011 | 216 | 0.090 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2010 | 81 | 0.090 |
Why?
|
| Staphylococcus aureus | 1 | 2014 | 548 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2014 | 677 | 0.090 |
Why?
|
| Intestines | 1 | 2014 | 686 | 0.090 |
Why?
|
| Prostaglandin Antagonists | 1 | 2008 | 6 | 0.090 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2014 | 363 | 0.090 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 987 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2015 | 3536 | 0.080 |
Why?
|
| Proton Pump Inhibitors | 1 | 2011 | 249 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2011 | 340 | 0.080 |
Why?
|
| Male | 12 | 2023 | 123000 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2011 | 417 | 0.080 |
Why?
|
| Neutrophil Activation | 1 | 2007 | 34 | 0.080 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2008 | 200 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 1538 | 0.080 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2007 | 84 | 0.080 |
Why?
|
| Chromatin | 1 | 2013 | 942 | 0.080 |
Why?
|
| Gastric Mucosa | 1 | 2011 | 613 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2015 | 5637 | 0.070 |
Why?
|
| Pedigree | 2 | 2020 | 1890 | 0.070 |
Why?
|
| Macrophages | 1 | 2012 | 1304 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 997 | 0.070 |
Why?
|
| Wound Healing | 1 | 2011 | 815 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 7548 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2008 | 644 | 0.060 |
Why?
|
| Thyroid Epithelial Cells | 1 | 2023 | 2 | 0.060 |
Why?
|
| NF-kappa B p52 Subunit | 1 | 2023 | 26 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2007 | 1487 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 461 | 0.060 |
Why?
|
| Reduced Folate Carrier Protein | 1 | 2023 | 20 | 0.060 |
Why?
|
| Signal Transduction | 4 | 2023 | 11965 | 0.060 |
Why?
|
| I-kappa B Proteins | 1 | 2023 | 170 | 0.060 |
Why?
|
| Electroretinography | 1 | 2023 | 116 | 0.060 |
Why?
|
| Loss of Function Mutation | 1 | 2023 | 132 | 0.060 |
Why?
|
| Cytokines | 1 | 2012 | 2809 | 0.060 |
Why?
|
| Fluorescein Angiography | 1 | 2023 | 139 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2023 | 294 | 0.050 |
Why?
|
| Female | 7 | 2019 | 141928 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2015 | 7226 | 0.050 |
Why?
|
| Interferons | 1 | 2023 | 291 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 4233 | 0.050 |
Why?
|
| Feces | 2 | 2015 | 770 | 0.050 |
Why?
|
| Phenotype | 2 | 2023 | 6295 | 0.050 |
Why?
|
| Mutation | 4 | 2023 | 15179 | 0.050 |
Why?
|
| Heterozygote | 1 | 2023 | 1020 | 0.050 |
Why?
|
| Adult | 4 | 2023 | 77950 | 0.050 |
Why?
|
| Apoptosis | 1 | 2015 | 7591 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2010 | 6100 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2007 | 1818 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 6089 | 0.050 |
Why?
|
| Retina | 1 | 2023 | 532 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2023 | 5710 | 0.040 |
Why?
|
| Rats, Wistar | 2 | 2011 | 562 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 1 | 2023 | 501 | 0.040 |
Why?
|
| Models, Biological | 1 | 2007 | 3254 | 0.040 |
Why?
|
| Homozygote | 1 | 2020 | 717 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 1084 | 0.040 |
Why?
|
| Child | 3 | 2023 | 29154 | 0.040 |
Why?
|
| Alleles | 1 | 2022 | 2437 | 0.030 |
Why?
|
| Pneumonia, Viral | 1 | 2023 | 715 | 0.030 |
Why?
|
| Biomarkers | 2 | 2022 | 5047 | 0.030 |
Why?
|
| Tongue | 1 | 2015 | 77 | 0.030 |
Why?
|
| Enterohemorrhagic Escherichia coli | 1 | 2014 | 9 | 0.030 |
Why?
|
| Middle Aged | 2 | 2012 | 86204 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2019 | 1152 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2023 | 16273 | 0.030 |
Why?
|
| Saliva | 1 | 2015 | 231 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2017 | 842 | 0.030 |
Why?
|
| Genotype | 1 | 2022 | 4109 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2015 | 490 | 0.030 |
Why?
|
| Permeability | 1 | 2012 | 167 | 0.030 |
Why?
|
| Denaturing Gradient Gel Electrophoresis | 1 | 2011 | 2 | 0.030 |
Why?
|
| Lansoprazole | 1 | 2011 | 19 | 0.030 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2011 | 25 | 0.030 |
Why?
|
| Naproxen | 1 | 2011 | 27 | 0.030 |
Why?
|
| Rats | 2 | 2011 | 6086 | 0.020 |
Why?
|
| Hematocrit | 1 | 2011 | 142 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2022 | 4053 | 0.020 |
Why?
|
| Gastric Acid | 1 | 2011 | 42 | 0.020 |
Why?
|
| Celecoxib | 1 | 2011 | 200 | 0.020 |
Why?
|
| Indomethacin | 1 | 2011 | 91 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2011 | 149 | 0.020 |
Why?
|
| Omeprazole | 1 | 2011 | 92 | 0.020 |
Why?
|
| Mucin 5AC | 1 | 2011 | 75 | 0.020 |
Why?
|
| Adolescent | 2 | 2023 | 31252 | 0.020 |
Why?
|
| Stomach Ulcer | 1 | 2011 | 95 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2011 | 553 | 0.020 |
Why?
|
| Pinacidil | 1 | 2009 | 2 | 0.020 |
Why?
|
| Glyburide | 1 | 2009 | 28 | 0.020 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2009 | 29 | 0.020 |
Why?
|
| Random Allocation | 1 | 2009 | 703 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 866 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 980 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 13310 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2009 | 1363 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 2307 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 3869 | 0.020 |
Why?
|
| Young Adult | 1 | 2023 | 21445 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2011 | 1471 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 12873 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2011 | 1823 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 4320 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 4971 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 12926 | 0.010 |
Why?
|
| Survival Rate | 1 | 2009 | 12221 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 37905 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2009 | 32848 | 0.000 |
Why?
|